Cargando…
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study
Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis and psoriatic arthritis. Japanese patients aged 20 years or more with moderate to severe plaque psoriasis and/or psoriatic arthritis were double‐blindly randomized 1:1 to tofacitinib 5 or 10 mg b.i.d. for 16 weeks...
Autores principales: | Asahina, Akihiko, Etoh, Takafumi, Igarashi, Atsuyuki, Imafuku, Shinichi, Saeki, Hidehisa, Shibasaki, Yoshiyuki, Tomochika, Yukiko, Toyoizumi, Shigeyuki, Nagaoka, Makoto, Ohtsuki, Mamitaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067558/ https://www.ncbi.nlm.nih.gov/pubmed/26875540 http://dx.doi.org/10.1111/1346-8138.13258 |
Ejemplares similares
-
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
por: Igarashi, Atsuyuki, et al.
Publicado: (2021) -
Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
por: Imafuku, Shinichi, et al.
Publicado: (2021) -
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
por: Asahina, Akihiko, et al.
Publicado: (2023) -
Diagnosis and Intervention in Early Psoriatic Arthritis
por: Hioki, Tomoyuki, et al.
Publicado: (2022) -
Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017)